Scott Rocklage has served as Chairman and CEO of Cubist Pharmaceuticals. He was also President, and CEO of Nycomed Salutar, a company that makes biopharmaceuticals. He has lead the research and development of three FDA-approved drugs: Omniscan, Teslascan, and Cubicin. Dr. Scott Rocklage has over thirty years of management experience within the healthcare industry.
Dr. Rocklage received a Bachelor of Science degree in Chemistry from Berkeley, The University of California and then went on to get his Ph.D. in Chemistry from the Massachusetts Institute of Technology(MIT). His insight and knowledge have helped to shape the pharmaceutical industry. Teslascan and Omniscan are both drugs that are injected intravenously, they are used to make lesions of the kidneys and liver, respectively, more visible.
How has Dr.Rocklage been able to do so much? In a recent interview, with ideamensch.com, Rocklage has said, “I am very well organized with regards to time management, calendaring and prioritization”.
5 AM Ventures
Rocklage has recently started a venture capital firm named “5 AM Ventures“. This venture capital firm funds biomedical start-ups in particular. Dr. Rocklage bets on the best companies he can find, some of them have come up with great products. The one that stands out the most is the needle-less injector, the Portal Prime. With the help of Dr.Rocklage’s firm, Portal Instruments was able to develop the Portal Prime. How does it work?
The Portal Prime delivers medication subcutaneously, intradermally, or intramuscularly. Rocklage on LinkedIn.
I can definitely imagine this being widely accepted first by pediatricians. Along with being easy to use, The Portal Prime also has been designed to integrate itself with an online app that can be accessed by third parties, like doctors, pharmacies, and insurers. These third parties can have a record of the data gathered by the device, and save it for future reference. Having all the information on one app would also make patient treatment seamless since doctors would be able to track a patient’s progress from their phone.